Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
1991-10-1
|
| pubmed:abstractText |
The autoradiographic 6-thioguanine-resistant mutant lymphocyte assay and a chromosome aberration assay were used to determine the time-course of appearance and persistence of elevated frequencies of hprt variants and dicentric chromosomes in patients receiving x-irradiation therapy. Twelve cancer patients, treated with 180-200 cGy/day, 5 days/wk, for 3-7 wk, were studied before treatment, at various weekly intervals during treatment, and after treatment. The hprt mutation assays were done with frozen/thawed lymphocytes isolated from aliquots of the same blood samples used for the chromosome aberration assays. The hprt variant frequencies (Vfs) of only 4 of the 7 patients assayed at 2 wk of treatment were elevated over pre-treatment Vfs, but during the 3rd and 4th weeks of treatment there were significant (P less than 0.01) 5- to 15-fold increases in all Vfs. By 6-32 wk after treatment Vfs had fallen to levels only slightly higher than the mean pre-treatment Vf. The frequencies of cells with dicentric chromosomes were significantly increased (P less than 0.01) after 1 wk of radiotherapy, continued to increase during therapy, and remained elevated after treatment. Five multiple sclerosis patients were also studied before and at 2 and 4 wk intervals after treatment with monthly i.v. doses of 750 mg/m2 of cyclophosphamide (CP). There were no significant elevations in chromosome aberrations at these post-treatment sample times. Previous assays for hprt mutants, done with aloquots of the same blood samples (Ammenheuser et al.: Mutat Res 204:509-520, 1988), had shown 8- to 20-fold increases in Vfs 2 wk after the 1st CP treatment. Our results demonstrate the complementary nature of these two human monitoring assays and emphasize the importance of careful selection of optimal sampling times.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0893-6692
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
18
|
| pubmed:geneSymbol |
hprt
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
126-35
|
| pubmed:dateRevised |
2007-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:1879404-Adult,
pubmed-meshheading:1879404-Aged,
pubmed-meshheading:1879404-Antineoplastic Agents,
pubmed-meshheading:1879404-Chromosome Aberrations,
pubmed-meshheading:1879404-Chromosomes,
pubmed-meshheading:1879404-Cyclophosphamide,
pubmed-meshheading:1879404-Drug Therapy,
pubmed-meshheading:1879404-Female,
pubmed-meshheading:1879404-Humans,
pubmed-meshheading:1879404-Hypoxanthine Phosphoribosyltransferase,
pubmed-meshheading:1879404-Lymphocytes,
pubmed-meshheading:1879404-Male,
pubmed-meshheading:1879404-Middle Aged,
pubmed-meshheading:1879404-Mutagenicity Tests,
pubmed-meshheading:1879404-Radiotherapy,
pubmed-meshheading:1879404-Time Factors,
pubmed-meshheading:1879404-Uterine Neoplasms,
pubmed-meshheading:1879404-X-Rays
|
| pubmed:year |
1991
|
| pubmed:articleTitle |
Comparison of hprt variant frequencies and chromosome aberration frequencies in lymphocytes from radiotherapy and chemotherapy patients: a prospective study.
|
| pubmed:affiliation |
Department of Preventive Medicine and Community Health, University of Texas Medical Branch, Galveston 77550.
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|